Yingli Fu1, Nicole Azene, Tina Ehtiati, Aaron Flammang, Wesley D Gilson, Kathleen Gabrielson, Clifford R Weiss, Jeff W M Bulte, Meiyappan Solaiyappan, Peter V Johnston, Dara L Kraitchman. 1. From the Division of MR Research, Russell H. Morgan Department of Radiology and Radiological Science (Y.F., C.R.W., J.W.M.B., M.S., D.L.K.), Department of Molecular and Comparative Pathobiology (N.A., K.G., D.L.K.), Institute for Cell Engineering (J.W.M.B.), and Division of Cardiology, Department of Internal Medicine (P.V.J.), The Johns Hopkins University School of Medicine, 600 N Wolfe St, 314 Park Bldg, Baltimore, MD 21087; and Department of Corporate Technology, Siemens Corporation, Baltimore, Md (T.E., A.F., W.D.G.).
Abstract
PURPOSE: To assess intrapericardial delivery of microencapsulated, xenogeneic human mesenchymal stem cells (hMSCs) by using x-ray fused with magnetic resonance (MR) imaging (x-ray/MR imaging) guidance as a potential treatment for ischemic cardiovascular disease in an immunocompetent swine model. MATERIALS AND METHODS: All animal experiments were approved by the institutional animal care and use committee. Stem cell microencapsulation was performed by using a modified alginate-poly-l-lysine-alginate encapsulation method to include 10% (wt/vol) barium sulfate to create barium-alginate microcapsules (BaCaps) that contained hMSCs. With x-ray/MR imaging guidance, eight female pigs (approximately 25 kg) were randomized to receive either BaCaps with hMSCs, empty BaCaps, naked hMSCs, or saline by using a percutaneous subxiphoid approach and were compared with animals that received empty BaCaps (n = 1) or BaCaps with hMSCs (n = 2) by using standard fluoroscopic delivery only. MR images and C-arm computed tomographic (CT) images were acquired before injection and 1 week after delivery. Animals were sacrificed immediately or at 1 week for histopathologic validation. Cardiac function between baseline and 1 week after delivery was evaluated by using a paired Student t test. RESULTS: hMSCs remained highly viable (94.8% ± 6) 2 days after encapsulation in vitro. With x-ray/MR imaging, successful intrapericardial access and delivery were achieved in all animals. BaCaps were visible fluoroscopically and at C-arm CT immediately and 1 week after delivery. Whereas BaCaps were free floating immediately after delivery, they consolidated into a pseudoepicardial tissue patch at 1 week, with hMSCs remaining highly viable within BaCaps; naked hMSCs were poorly retained. Follow-up imaging 1 week after x-ray/MR imaging-guided intrapericardial delivery showed no evidence of pericardial adhesion and/or effusion or adverse effect on cardiac function. In contradistinction, BaCaps delivery with x-ray fluoroscopy without x-ray/MR imaging (n = 3) resulted in pericardial adhesions and poor hMSC viability after 1 week. CONCLUSION: Intrapericardial delivery of BaCaps with hMSCs leads to high cell retention and survival. With x-ray/MR imaging guidance, intrapericardial delivery can be performed safely in the absence of preexisting pericardial effusion to provide a novel route for cardiac cellular regenerative therapy.
PURPOSE: To assess intrapericardial delivery of microencapsulated, xenogeneic human mesenchymal stem cells (hMSCs) by using x-ray fused with magnetic resonance (MR) imaging (x-ray/MR imaging) guidance as a potential treatment for ischemic cardiovascular disease in an immunocompetent swine model. MATERIALS AND METHODS: All animal experiments were approved by the institutional animal care and use committee. Stem cell microencapsulation was performed by using a modified alginate-poly-l-lysine-alginate encapsulation method to include 10% (wt/vol) barium sulfate to create barium-alginate microcapsules (BaCaps) that contained hMSCs. With x-ray/MR imaging guidance, eight female pigs (approximately 25 kg) were randomized to receive either BaCaps with hMSCs, empty BaCaps, naked hMSCs, or saline by using a percutaneous subxiphoid approach and were compared with animals that received empty BaCaps (n = 1) or BaCaps with hMSCs (n = 2) by using standard fluoroscopic delivery only. MR images and C-arm computed tomographic (CT) images were acquired before injection and 1 week after delivery. Animals were sacrificed immediately or at 1 week for histopathologic validation. Cardiac function between baseline and 1 week after delivery was evaluated by using a paired Student t test. RESULTS: hMSCs remained highly viable (94.8% ± 6) 2 days after encapsulation in vitro. With x-ray/MR imaging, successful intrapericardial access and delivery were achieved in all animals. BaCaps were visible fluoroscopically and at C-arm CT immediately and 1 week after delivery. Whereas BaCaps were free floating immediately after delivery, they consolidated into a pseudoepicardial tissue patch at 1 week, with hMSCs remaining highly viable within BaCaps; naked hMSCs were poorly retained. Follow-up imaging 1 week after x-ray/MR imaging-guided intrapericardial delivery showed no evidence of pericardial adhesion and/or effusion or adverse effect on cardiac function. In contradistinction, BaCaps delivery with x-ray fluoroscopy without x-ray/MR imaging (n = 3) resulted in pericardial adhesions and poor hMSC viability after 1 week. CONCLUSION: Intrapericardial delivery of BaCaps with hMSCs leads to high cell retention and survival. With x-ray/MR imaging guidance, intrapericardial delivery can be performed safely in the absence of preexisting pericardial effusion to provide a novel route for cardiac cellular regenerative therapy.
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2011-12-15 Impact factor: 29.690
Authors: Remedios Guadalupe Gomez-Mauricio; Argia Acarregui; Francisco Miguel Sánchez-Margallo; Verónica Crisóstomo; Ignacio Gallo; Rosa María Hernández; José Luis Pedraz; Gorka Orive; María Fernanda Martín-Cancho Journal: Eur J Pharm Biopharm Date: 2012-12-21 Impact factor: 5.571
Authors: R J Laham; M Rezaee; M Post; D Novicki; F W Sellke; J D Pearlman; M Simons; D Hung Journal: J Pharmacol Exp Ther Date: 2000-02 Impact factor: 4.030
Authors: Dorota A Kedziorek; Lawrence V Hofmann; Yingli Fu; Wesley D Gilson; Kenyatta M Cosby; Bernard Kohl; Brad P Barnett; Brian W Simons; Piotr Walczak; Jeff W M Bulte; Kathleen Gabrielson; Dara L Kraitchman Journal: Stem Cells Date: 2012-06 Impact factor: 6.277
Authors: Joshua M Hare; Joel E Fishman; Gary Gerstenblith; Darcy L DiFede Velazquez; Juan P Zambrano; Viky Y Suncion; Melissa Tracy; Eduard Ghersin; Peter V Johnston; Jeffrey A Brinker; Elayne Breton; Janice Davis-Sproul; Ivonne H Schulman; John Byrnes; Adam M Mendizabal; Maureen H Lowery; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Phillip Ruiz; Alexandra Amador; Jose Da Silva; Ian K McNiece; Alan W Heldman; Richard George; Albert Lardo Journal: JAMA Date: 2012-12-12 Impact factor: 56.272
Authors: Verónica Crisóstomo; Claudia Baéz-Diaz; Virginia Blanco-Blázquez; Verónica Álvarez; Esther López-Nieto; Juan Maestre; Antoni Bayes-Genis; Carolina Gálvez-Montón; Javier G Casado; Francisco M Sánchez-Margallo Journal: Sci Rep Date: 2021-11-12 Impact factor: 4.379
Authors: Cyrus W Beh; Yingli Fu; Clifford R Weiss; Charles Hu; Aravind Arepally; Hai-Quan Mao; Tza-Huei Wang; Dara L Kraitchman Journal: Lab Chip Date: 2020-09-01 Impact factor: 6.799
Authors: Clifford R Weiss; Yingli Fu; Cyrus Beh; Charles Hu; Dorota Kedziorek; Eun-Ji Shin; Robert A Anders; Aravind Arepally; Dara L Kraitchman Journal: J Vasc Interv Radiol Date: 2020-08-14 Impact factor: 3.464